Zobrazeno 1 - 10
of 1 076
pro vyhledávání: '"mechanistic PK/PD"'
Autor:
Shahraz, Azar1 (AUTHOR) shahraz.azar@gmail.com, Penney, Mark2 (AUTHOR), Candido, Juliana3 (AUTHOR), Opoku‐Ansah, Grace3 (AUTHOR), Neubauer, Melanie3 (AUTHOR), Eyles, Jim3 (AUTHOR), Ojo, Oluwaseun3 (AUTHOR), Liu, Nelson3 (AUTHOR), Luheshi, Nadia M.3 (AUTHOR), Phipps, Alex4 (AUTHOR), Vishwanathan, Karthick1 (AUTHOR)
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. Oct2024, Vol. 13 Issue 10, p1670-1681. 12p.
Autor:
Azar Shahraz, Mark Penney, Juliana Candido, Grace Opoku‐Ansah, Melanie Neubauer, Jim Eyles, Oluwaseun Ojo, Nelson Liu, Nadia M. Luheshi, Alex Phipps, Karthick Vishwanathan
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 10, Pp 1670-1681 (2024)
Abstract AZD0171 (INN: Falbikitug) is being developed as a humanized monoclonal antibody (mAb), immunoglobulin G subclass 1 (IgG1), which binds specifically to the immunosuppressive human cytokine leukemia inhibitory factor (LIF) and inhibits downstr
Externí odkaz:
https://doaj.org/article/654650c22c3e43b7a045471ce1fdd1d4
Autor:
Li, Qian, Geng, Taohua, Li, Haiyan, Zheng, Shuquan, Svedlund, Sara, Gan, Liming, Egnell, Ann-Charlotte, Gao, Shan, Chen, Rui, Hu, Pei
Publikováno v:
In Heliyon 15 June 2024 10(11)
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTEarly assessment of dosing requirements should be an integral part of developability assessments for a discovery program. If a very high dose is required to achieve the desired pharmacological effect, it may not be clinically feasible or comm
Externí odkaz:
https://doaj.org/article/79d0603ae4e541328cf770782700ba6a
Autor:
Michalon A; Neurimmune, Schlieren, Switzerland., Renaud L; LYO-X, Basel, Switzerland., Machacek M; LYO-X, Basel, Switzerland., Cortijo C; Neurimmune, Schlieren, Switzerland., Udata C; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA., Mercuri MF; Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA., Buller F; Neurimmune, Schlieren, Switzerland., Hock C; Neurimmune, Schlieren, Switzerland.; Institute for Regenerative Medicine, University of Zurich, Schlieren, Switzerland., Nitsch RM; Neurimmune, Schlieren, Switzerland.; Institute for Regenerative Medicine, University of Zurich, Schlieren, Switzerland., Kahr PC; Neurimmune, Schlieren, Switzerland.; Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland., Grimm J; Neurimmune, Schlieren, Switzerland.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2025 Jan; Vol. 117 (1), pp. 261-269. Date of Electronic Publication: 2024 Oct 15.
Autor:
Srinivasan B; AstraZeneca UK Limited, Cambridge, UK.
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2024 Nov; Vol. 181 (21), pp. 4089-4090. Date of Electronic Publication: 2024 Sep 15.
Autor:
Qian Li, Taohua Geng, Haiyan Li, Shuquan Zheng, Sara Svedlund, Liming Gan, Ann-Charlotte Egnell, Shan Gao, Rui Chen, Pei Hu
Publikováno v:
Heliyon, Vol 10, Iss 11, Pp e31924- (2024)
Small interference RNA (siRNA) is a class of short double-stranded RNA molecules that cause mRNA degradation through an RNA interference mechanism and is a promising therapeutic modality. RBD1016 is a siRNA drug in clinical development for the treatm
Externí odkaz:
https://doaj.org/article/6797ab69ec9547f5891b25d823ad80a4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rymut, Sharon M.1 (AUTHOR), Henderson, Lindsay M.1 (AUTHOR), Poon, Victor1 (AUTHOR), Staton, Tracy L.2 (AUTHOR), Cai, Fang2 (AUTHOR), Sukumaran, Siddharth3 (AUTHOR), Rhee, Horace4 (AUTHOR), Owen, Ryan1 (AUTHOR), Ramanujan, Saroja3 (AUTHOR), Yoshida, Kenta1 (AUTHOR) yoshida.kenta@gene.com
Publikováno v:
CTS: Clinical & Translational Science. Apr2023, Vol. 16 Issue 4, p694-703. 10p.